Neutron Capture Therapy with Gd-DTPA in Tumor-Bearing Rats
Neutron Capture Therapy with Gd-DTPA in Tumor-Bearing Rats
复制标题
Gd-DTPA 对荷瘤大鼠的中子捕获疗法
DOI:
10.1007/978-1-4757-9567-7_123
复制
发表时间:
1996
期刊:
影响因子:
--
通讯作者:
R. Lawaczeck
中科院分区:
文献类型:
--
作者:
V. Khokhlov;P. N. Yashkin;D. Silin;E. S. Djorova;R. Lawaczeck
Gd-DTPA dimeglumine (Magnevist®) is widely used as contrast medium in magnetic resonance imaging (MRI). It is especially helpful for the delineation of brain tumors with an injured blood-brain barrier’. The dianion [Gd-DTPA]2−diffuses into the tumorous tissue and due to the large magnetic moment of the Gd3+-ion leads to a shortening of the water relaxation times’ and, consequently, to changes of the MRI signal intensities2. A number of pharmacologically well-tolerated Gd-complexes are clinically available or under clinical development. In addition to its diagnostic value,157Gd with a natural abundance of 15.7% has the highest cross-section (255 000 barn (=10−24cm2)) for thermal neutrons of all stable isotopes. Natural Gd has an average cross-section of 48 800 barn. After neutron capture the excited Gd-nuclei relax via the emission of photons with energies up to 7.9 MeV and a cascade of conversion and Auger electrons. Therefore, Gd-complexes have been suggested as agents for neutron capture therapy (NCT)3–6and NCT effects of Gd-complexes have been studied in phantoms’, on the DNA level’, and in bothin vitroandin vivosystems9–13 Atherapeutic gain has been demonstrated experimentally for extracellular Gd-complexes9–13although the discussion on the contributions of prompt γ’s or electrons to the therapeutic effect is not yet settled. In the following we report on experiments performed with a rat tumor model and administration of Gd-DTPA prior to irradiation with epithermal neutrons.